Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

This Big Pharma's Big Bet Is Paying Off

By Dave Williamson - Apr 16, 2013 at 6:04PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

NYSE: LLY

Eli Lilly and Company

Market Cap

$276B

Today's Change

(2.10%) $6.45

Current Price

$313.46

Price as of May 26, 2022, 4:00 p.m. ET

Eli Lilly is betting big, and it's working.

With the prospect of losing a third of its revenue because of patent expiration in 2014, Eli Lilly has bet big on oncology and diabetes drugs. In this video, David Williamson highlights the success so far, and the possible challenges, for Lilly's diabetes drug, dulaglutide. Type 2 diabetes is a big problem, and David says Lilly seems well positioned to benefit from its growing prevalence, although investors need to remember there will be some patent-expiration bumps along the way. Check out the video for more details.

Stocks Mentioned

Eli Lilly and Company

LLY

$313.46 (2.10%) $6.45

Merck & Co., Inc.

MRK

$92.31 (-1.54%) $-1.44

Sanofi

SNY

$55.50 (-0.63%) $0.35

AstraZeneca PLC

AZN

$66.70 (-0.17%) $0.11

Novo Nordisk A/S

NVO

$106.60 (1.28%) $1.35

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Why This FDA Approval Is a Game Changer for Eli Lilly

Why Eli Lilly Stock Climbed Today

Got $10,000? These 3 Growth Stocks Also Pay Dividends

Here's My Top Pharma Stock to Buy in May

Eli Lilly and Company (LLY) Q1 2022 Earnings Call Transcript

Motley Fool Returns

Market-beating stocks from our award-winning service.

Stock Advisor Returns

332%

S&P 500 Returns

118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Join Stock Advisor

Cumulative Growth of a $10,000 Investment in Stock Advisor

Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.